LinkedIn Profile

Access NanOlogy historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:nanology 18238793 Apr 21st, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 21st, 2024 07:04AM Apr 21st, 2024 07:04AM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 20th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 20th, 2024 06:02AM Apr 20th, 2024 09:20PM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 19th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 19th, 2024 08:30AM Apr 19th, 2024 08:30AM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 18th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 18th, 2024 07:09AM Apr 19th, 2024 04:54AM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 17th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 17th, 2024 08:30AM Apr 17th, 2024 07:09PM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 16th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 16th, 2024 06:01AM Apr 16th, 2024 03:27PM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 15th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 15th, 2024 08:50AM Apr 15th, 2024 09:06PM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 14th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 14th, 2024 04:51AM Apr 14th, 2024 04:51AM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 13th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 13th, 2024 03:45AM Apr 13th, 2024 03:49PM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy
private:nanology 18238793 Apr 12th, 2024 12:00AM NanOlogy 1.2K 7.00 Open Apr 12th, 2024 03:57AM Apr 12th, 2024 12:56PM Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. Technology: The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic Potential: Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. Open Oncology drug development and Intratumoral therapy Open 3909 Hulen Street Fort Worth TX US 76107 NanOlogy

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.